Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides

As the most frequently occurring cancer worldwide, breast cancer (BC) is the leading cause of cancer-related death in women. The overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 15% of BC patients, and it is often associated with a poor prognosis due to the effect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shushan Ge, Jihui Li, Yu Yu, Zhengguo Chen, Yi Yang, Liqing Zhu, Shibiao Sang, Shengming Deng
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	breast cancer HER2 radionuclide molecular probes molecular imaging clinical trials Organic chemistry QD241-441
Acceso en línea:	https://doaj.org/article/ccab3b07725c4edb8ab11beaf61ca8a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ccab3b07725c4edb8ab11beaf61ca8a7
record_format	dspace
spelling	oai:doaj.org-article:ccab3b07725c4edb8ab11beaf61ca8a72021-11-11T18:29:00ZReview: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides10.3390/molecules262164821420-3049https://doaj.org/article/ccab3b07725c4edb8ab11beaf61ca8a72021-10-01T00:00:00Zhttps://www.mdpi.com/1420-3049/26/21/6482https://doaj.org/toc/1420-3049As the most frequently occurring cancer worldwide, breast cancer (BC) is the leading cause of cancer-related death in women. The overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 15% of BC patients, and it is often associated with a poor prognosis due to the effect on cell proliferation, migration, invasion, and survival. As a result of the heterogeneity of BC, molecular imaging with HER2 probes can non-invasively, in real time, and quantitatively reflect the expression status of HER2 in tumors. This will provide a new approach for patients to choose treatment options and monitor treatment response. Furthermore, radionuclide molecular imaging has the potential of repetitive measurements, and it can help solve the problem of heterogeneous expression and conversion of HER2 status during disease progression or treatment. Different imaging probes of targeting proteins, such as monoclonal antibodies, antibody fragments, nanobodies, and affibodies, are currently in preclinical and clinical development. Moreover, in recent years, HER2-specific peptides have been widely developed for molecular imaging techniques for HER2-positive cancers. This article summarized different types of molecular probes targeting HER2 used in current clinical applications and the developmental trend of some HER2-specific peptides.Shushan GeJihui LiYu YuZhengguo ChenYi YangLiqing ZhuShibiao SangShengming DengMDPI AGarticlebreast cancerHER2radionuclide molecular probesmolecular imagingclinical trialsOrganic chemistryQD241-441ENMolecules, Vol 26, Iss 6482, p 6482 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer HER2 radionuclide molecular probes molecular imaging clinical trials Organic chemistry QD241-441
spellingShingle	breast cancer HER2 radionuclide molecular probes molecular imaging clinical trials Organic chemistry QD241-441 Shushan Ge Jihui Li Yu Yu Zhengguo Chen Yi Yang Liqing Zhu Shibiao Sang Shengming Deng Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
description	As the most frequently occurring cancer worldwide, breast cancer (BC) is the leading cause of cancer-related death in women. The overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 15% of BC patients, and it is often associated with a poor prognosis due to the effect on cell proliferation, migration, invasion, and survival. As a result of the heterogeneity of BC, molecular imaging with HER2 probes can non-invasively, in real time, and quantitatively reflect the expression status of HER2 in tumors. This will provide a new approach for patients to choose treatment options and monitor treatment response. Furthermore, radionuclide molecular imaging has the potential of repetitive measurements, and it can help solve the problem of heterogeneous expression and conversion of HER2 status during disease progression or treatment. Different imaging probes of targeting proteins, such as monoclonal antibodies, antibody fragments, nanobodies, and affibodies, are currently in preclinical and clinical development. Moreover, in recent years, HER2-specific peptides have been widely developed for molecular imaging techniques for HER2-positive cancers. This article summarized different types of molecular probes targeting HER2 used in current clinical applications and the developmental trend of some HER2-specific peptides.
format	article
author	Shushan Ge Jihui Li Yu Yu Zhengguo Chen Yi Yang Liqing Zhu Shibiao Sang Shengming Deng
author_facet	Shushan Ge Jihui Li Yu Yu Zhengguo Chen Yi Yang Liqing Zhu Shibiao Sang Shengming Deng
author_sort	Shushan Ge
title	Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
title_short	Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
title_full	Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
title_fullStr	Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
title_full_unstemmed	Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
title_sort	review: radionuclide molecular imaging targeting her2 in breast cancer with a focus on molecular probes into clinical trials and small peptides
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ccab3b07725c4edb8ab11beaf61ca8a7
work_keys_str_mv	AT shushange reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT jihuili reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT yuyu reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT zhengguochen reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT yiyang reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT liqingzhu reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT shibiaosang reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT shengmingdeng reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides
_version_	1718431850514350080

Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides

Ejemplares similares